Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2021 - 2023)

Insight Molecular Diagnostics (IMDX) has 3 years of Liabilities from Discontinued Operations data on file, last reported at 45000.0 in Q4 2023.

• Quarterly Liabilities from Discontinued Operations fell 97.76% year-over-year to 45000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 45000.0 (down 97.76% YoY) and the FY2023 annual result came in at 45000.0, down 97.76% from the prior year.
• Liabilities from Discontinued Operations declined to 45000.0 in Q4 2023 per IMDX's latest filing, from 90000.0 in the prior quarter.
• The five-year high for Liabilities from Discontinued Operations was 2005000.0 in Q4 2022, with the low at 45000.0 in Q4 2023.
• Average Liabilities from Discontinued Operations over 3 years is 672833.33, with a median of 185500.0 recorded in 2023.
• Year-over-year, Liabilities from Discontinued Operations jumped 31.39% in 2022 and plunged 97.76% in 2023.
• Insight Molecular Diagnostics' Liabilities from Discontinued Operations stood at 1526000.0 in 2021, then jumped by 31.39% to 2005000.0 in 2022, then sank by 97.76% to 45000.0 in 2023.
• Business Quant data shows IMDX's Liabilities from Discontinued Operations at 45000.0 in Q4 2023, 90000.0 in Q3 2023, and 135000.0 in Q2 2023.